Literature DB >> 10367700

Apolipoprotein E genotype and progression of Alzheimer's disease: the Rotterdam Study.

A J Slooter1, J J Houwing-Duistermaat, F van Harskamp, M Cruts, C Van Broeckhoven, M M Breteler, A Hofman, T Stijnen, C M van Duijn.   

Abstract

The APOE*4 allele of the apolipoprotein E gene increases the risk of Alzheimer's disease (AD), but whether it also affects the course of the disease is controversial. However, all studies on this issue until now have been based on patients at various stages of disease. In the present population-based study, 97 patients were included at a similar stage, i.e., before the onset of symptoms, and followed for up to 5 years. We found that the APOE*4 allele is not a strong determinant of survival in AD. As change in cognitive function and severity of dementia are similar for AD patients with and without APOE*4, our study suggests that progression of AD is not related to the APOE*4 allele.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10367700     DOI: 10.1007/s004150050351

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  16 in total

1.  Caregiver-recipient closeness and symptom progression in Alzheimer disease. The Cache County Dementia Progression Study.

Authors:  Maria C Norton; Kathleen W Piercy; Peter V Rabins; Robert C Green; John C S Breitner; Truls Ostbye; Christopher Corcoran; Kathleen A Welsh-Bohmer; Constantine G Lyketsos; Joann T Tschanz
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  2009-06-29       Impact factor: 4.077

2.  Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts.

Authors:  Susan M Resnick; Murat Bilgel; Abhay Moghekar; Yang An; Qing Cai; Mei-Cheng Wang; Madhav Thambisetty; Jerry L Prince; Yun Zhou; Anja Soldan; Dean F Wong; Richard J O'Brien; Luigi Ferrucci; Marilyn S Albert
Journal:  Neurobiol Aging       Date:  2015-04-04       Impact factor: 4.673

3.  Factors affecting survival of patients with neurodegenerative disease.

Authors:  Kyle Steenland; Jessica MacNeil; Ryan Seals; Allan Levey
Journal:  Neuroepidemiology       Date:  2010-04-08       Impact factor: 3.282

4.  Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations.

Authors:  A M Cataldo; C M Peterhoff; J C Troncoso; T Gomez-Isla; B T Hyman; R A Nixon
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

5.  Survival in Alzheimer disease: a multiethnic, population-based study of incident cases.

Authors:  E P Helzner; N Scarmeas; S Cosentino; M X Tang; N Schupf; Y Stern
Journal:  Neurology       Date:  2008-11-04       Impact factor: 9.910

6.  Genetic Determinants of Survival in Patientswith Alzheimer’s Disease.

Authors:  Xingbin Wang; Oscar Lopez; Robert A Sweet; James T Becker; Steven T DeKosky; Mahmud M Barmada; Eleanor Feingold; F Yesim Demirci; M Ilyas Kamboh
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 7.  Apolipoprotein E, gender, and Alzheimer's disease: an overlooked, but potent and promising interaction.

Authors:  Leo Ungar; Andre Altmann; Michael D Greicius
Journal:  Brain Imaging Behav       Date:  2014-06       Impact factor: 3.978

8.  The FAS gene, brain volume, and disease progression in Alzheimer's disease.

Authors:  Deniz Erten-Lyons; Anne Jacobson; Patricia Kramer; Andrew Grupe; Jeffrey Kaye
Journal:  Alzheimers Dement       Date:  2009-09-18       Impact factor: 21.566

9.  APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease.

Authors:  S Cosentino; N Scarmeas; E Helzner; M M Glymour; J Brandt; M Albert; D Blacker; Y Stern
Journal:  Neurology       Date:  2008-04-09       Impact factor: 9.910

10.  Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer's disease.

Authors:  K J H Robson; D J Lehmann; V L C Wimhurst; K J Livesey; M Combrinck; A T Merryweather-Clarke; D R Warden; A D Smith
Journal:  J Med Genet       Date:  2004-04       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.